Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange.

Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how. In oncology, the pipeline includes TroVax^®, a cancer immunotherapy, which was recently licensed to sanofi-aventis for global development and commercialisation. TroVax is in Phase III development for renal cancer and sanofi-aventis is implementing a development plan for metastatic colorectal cancer. The recent acquisition of Oxxon Therapeutics adds a Phase II cancer immunotherapy for melanoma, HI-8 MEL^®, to the Company's pipeline. Other oncology product candidates include a gene therapy, MetXia^®, which is in Phase II development for pancreatic cancer, and a preclinical targeted antibody therapy, which is being developed in collaboration with Wyeth. In neurotherapy, the Company's lead product, ProSavin, is expected to enter clinical trials in Parkinson's disease in 2007. The preclinical pipeline includes gene-based products for vision loss, motor neuron disease and nerve repair. The acquisition of Oxxon also provides a platform for the development of therapeutic vaccines for infectious diseases.

The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 75 split between its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. In addition to the TroVax collaboration with sanofi-aventis and the targeted antibody therapy collaboration with Wyeth, Oxford BioMedica has corporate collaborations with Intervet, Sigma-Aldrich, Viragen, MolMed and Virxsys; and has licensed technology to a number of companies including Merck & Co, Biogen Idec, GlaxoSmithKline and Pfizer.